Malken Bayrakdarian
Direktor/Vorstandsmitglied bei NuChem Sciences, Inc.
Profil
Malken Bayrakdarian currently works as an Executive Director at NuChem Sciences, Inc.
Aktive Positionen von Malken Bayrakdarian
Unternehmen | Position | Beginn |
---|---|---|
NuChem Sciences, Inc.
NuChem Sciences, Inc. BiotechnologyHealth Technology Part of Sygnature Discovery Ltd., NuChem Sciences, Inc. was founded in 2011 and is a leading contract research organization in drug discovery and chemical development. The company is based in Saint-Laurent, Canada. NuChem Sciences, which employs 300 scientific and support staff, offers a range of standalone and integrated discovery services in chemistry, biochemistry, in-vitro biology, DMPK, structural biology, and in vivo pharmacology. NuChem Sciences' expert chemistry services for drug discovery feature synthetic, medicinal, and analytical solutions. The Canadian company also offers advanced ADME studies, metabolic stability analysis, and tailored solutions for drug discovery. NuChem Sciences was acquired by Sygnature Discovery Ltd. on July 31, 2023. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
NuChem Sciences, Inc.
NuChem Sciences, Inc. BiotechnologyHealth Technology Part of Sygnature Discovery Ltd., NuChem Sciences, Inc. was founded in 2011 and is a leading contract research organization in drug discovery and chemical development. The company is based in Saint-Laurent, Canada. NuChem Sciences, which employs 300 scientific and support staff, offers a range of standalone and integrated discovery services in chemistry, biochemistry, in-vitro biology, DMPK, structural biology, and in vivo pharmacology. NuChem Sciences' expert chemistry services for drug discovery feature synthetic, medicinal, and analytical solutions. The Canadian company also offers advanced ADME studies, metabolic stability analysis, and tailored solutions for drug discovery. NuChem Sciences was acquired by Sygnature Discovery Ltd. on July 31, 2023. | Health Technology |